788 related articles for article (PubMed ID: 23817077)
21. CUDC-305, a novel synthetic HSP90 inhibitor with unique pharmacologic properties for cancer therapy.
Bao R; Lai CJ; Qu H; Wang D; Yin L; Zifcak B; Atoyan R; Wang J; Samson M; Forrester J; DellaRocca S; Xu GX; Tao X; Zhai HX; Cai X; Qian C
Clin Cancer Res; 2009 Jun; 15(12):4046-57. PubMed ID: 19509149
[TBL] [Abstract][Full Text] [Related]
22. The use of animal models in cancer drug discovery and development.
Curt GA
Stem Cells; 1994 Jan; 12(1):23-9. PubMed ID: 8142918
[TBL] [Abstract][Full Text] [Related]
23. In Vivo Pharmacology Models for Cancer Target Research.
Chen D; An X; Ouyang X; Cai J; Zhou D; Li QX
Methods Mol Biol; 2019; 1953():183-211. PubMed ID: 30912023
[TBL] [Abstract][Full Text] [Related]
24. Targeted approaches to childhood cancer: progress in drug discovery and development.
Hirsch S; Marshall LV; Carceller Lechon F; Pearson AD; Moreno L
Expert Opin Drug Discov; 2015 May; 10(5):483-95. PubMed ID: 25840490
[TBL] [Abstract][Full Text] [Related]
25. Of mice and men: values and liabilities of the athymic nude mouse model in anticancer drug development.
Kelland LR
Eur J Cancer; 2004 Apr; 40(6):827-36. PubMed ID: 15120038
[TBL] [Abstract][Full Text] [Related]
26. Advances in patient-derived tumor xenografts: from target identification to predicting clinical response rates in oncology.
Rosfjord E; Lucas J; Li G; Gerber HP
Biochem Pharmacol; 2014 Sep; 91(2):135-43. PubMed ID: 24950467
[TBL] [Abstract][Full Text] [Related]
27. Primary human non-small cell lung and pancreatic tumorgraft models--utility and applications in drug discovery and tumor biology.
Calles A; Rubio-Viqueira B; Hidalgo M
Curr Protoc Pharmacol; 2013 Jun; Chapter 14():Unit 14.26. PubMed ID: 23744711
[TBL] [Abstract][Full Text] [Related]
28. Preclinical in vitro models from genetically engineered mice for breast and colon cancer (Review).
Telang N; Katdare M
Oncol Rep; 2011 May; 25(5):1195-201. PubMed ID: 21399881
[TBL] [Abstract][Full Text] [Related]
29. Orthotopic models of esophageal carcinoma and their use in drug discovery.
Gros SJ
Curr Protoc Pharmacol; 2011 Sep; Chapter 14():Unit14.20. PubMed ID: 21898333
[TBL] [Abstract][Full Text] [Related]
30. Mathematical modeling for novel cancer drug discovery and development.
Zhang P; Brusic V
Expert Opin Drug Discov; 2014 Oct; 9(10):1133-50. PubMed ID: 25062617
[TBL] [Abstract][Full Text] [Related]
31. Comparative profiling of the novel epothilone, sagopilone, in xenografts derived from primary non-small cell lung cancer.
Hammer S; Sommer A; Fichtner I; Becker M; Rolff J; Merk J; Klar U; Hoffmann J
Clin Cancer Res; 2010 Mar; 16(5):1452-65. PubMed ID: 20179216
[TBL] [Abstract][Full Text] [Related]
32. How can attrition rates be reduced in cancer drug discovery?
Moreno L; Pearson AD
Expert Opin Drug Discov; 2013 Apr; 8(4):363-8. PubMed ID: 23373702
[TBL] [Abstract][Full Text] [Related]
33. Patient-derived tumour xenografts as models for breast cancer drug development.
Marangoni E; Poupon MF
Curr Opin Oncol; 2014 Nov; 26(6):556-61. PubMed ID: 25188472
[TBL] [Abstract][Full Text] [Related]
34. The use of targeted mouse models for preclinical testing of novel cancer therapeutics.
Olive KP; Tuveson DA
Clin Cancer Res; 2006 Sep; 12(18):5277-87. PubMed ID: 17000660
[TBL] [Abstract][Full Text] [Related]
35. Oncology drug discovery: planning a turnaround.
Toniatti C; Jones P; Graham H; Pagliara B; Draetta G
Cancer Discov; 2014 Apr; 4(4):397-404. PubMed ID: 24706659
[TBL] [Abstract][Full Text] [Related]
36. Discovery of novel drugs for promising targets.
Martell RE; Brooks DG; Wang Y; Wilcoxen K
Clin Ther; 2013 Sep; 35(9):1271-81. PubMed ID: 24054704
[TBL] [Abstract][Full Text] [Related]
37. Priceless GEMMs: genetically engineered mouse models for colorectal cancer drug development.
Roper J; Hung KE
Trends Pharmacol Sci; 2012 Aug; 33(8):449-55. PubMed ID: 22739258
[TBL] [Abstract][Full Text] [Related]
38. The mighty mouse: genetically engineered mouse models in cancer drug development.
Sharpless NE; Depinho RA
Nat Rev Drug Discov; 2006 Sep; 5(9):741-54. PubMed ID: 16915232
[TBL] [Abstract][Full Text] [Related]
39. Harnessing preclinical mouse models to inform human clinical cancer trials.
Gutmann DH; Hunter-Schaedle K; Shannon KM
J Clin Invest; 2006 Apr; 116(4):847-52. PubMed ID: 16585951
[TBL] [Abstract][Full Text] [Related]
40. Overview of human primary tumorgraft models: comparisons with traditional oncology preclinical models and the clinical relevance and utility of primary tumorgrafts in basic and translational oncology research.
Lum DH; Matsen C; Welm AL; Welm BE
Curr Protoc Pharmacol; 2012 Dec; Chapter 14():Unit 14.22. PubMed ID: 23258598
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
